Octreotide + Placebo

Phase 2/3Completed

1 views this week 0 watching💤 Quiet

Interest: 38/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Polycystic Kidney, Autosomal Dominant

Conditions

Polycystic Kidney, Autosomal Dominant, Polycystic Liver Disease, Hepatomegaly, Liver Diseases, Kidney, Polycystic, Abdominal Pain

Trial Timeline

Jan 1, 2007 → Oct 1, 2008

NCT ID

NCT00426153

About Octreotide + Placebo

Octreotide + Placebo is a phase 2/3 stage product being developed by Novartis for Polycystic Kidney, Autosomal Dominant. The current trial status is completed. This product is registered under clinical trial identifier NCT00426153. Target conditions include Polycystic Kidney, Autosomal Dominant, Polycystic Liver Disease, Hepatomegaly.

What happened to similar drugs?

3 of 14 similar drugs in Polycystic Kidney, Autosomal Dominant were approved

Approved (3) Terminated (4) Active (7)

✅tredaptive (nicotinic acid/ laropiprant) + placeboMerckApproved

✅Placebo + EverolimusNovartisApproved

✅3 mg DRSP/20 μg EEBayerApproved

🔄Metformin XR + Saxagliptin + Saxagliptin-Metformin XRAstraZenecaPhase 3

🔄Exenatide once weekly (EQW ) + Dapagliflozin (DAPA) + EQW plus DAPA + Dapagliflozin plus Glucophage (MET ER) + Phentermine /Topiramate (PHEN/ TPM) ERAstraZenecaPhase 3

🔄Lisinopril + Telmisartan + PlaceboMerckPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00426153	Phase 2/3	Completed	Jan 1, 2007	Oct 1, 2008	Polycystic Kidney, Autosomal Dominant
NCT00399893	Pre-clinical	Terminated	Dec 1, 2006	Sep 1, 2010	Prader-Willi Syndrome

Competing Products

20 competing products in Polycystic Kidney, Autosomal Dominant

See all competitors

Product	Company	Stage	Hype Score
Tildacerfont + Placebo	Spruce Biosciences	Phase 2	17
ABBV-CLS-628 + Placebo	AbbVie	Phase 2	42
Elagolix + Placebo	AbbVie	Phase 2	35
Metformin XR + Saxagliptin + Saxagliptin-Metformin XR	AstraZeneca	Phase 3	40
Exenatide once weekly (EQW ) + Dapagliflozin (DAPA) + EQW plus DAPA + Dapagliflozin plus Glucophage (MET ER) + Phentermine /Topiramate (PHEN/ TPM) ER	AstraZeneca	Phase 3	40
AZD1613 - Part A + Placebo - Part A + AZD1613 - Part B + Placebo - Part B	AstraZeneca	Phase 1	36
AZD4901 (oral) + Placebo to match AZD4901	AstraZeneca	Phase 2	35
IVF Antagonist Protocol	Merck	Pre-clinical	22
tredaptive (nicotinic acid/ laropiprant) + placebo	Merck	Approved	43
Lisinopril + Telmisartan + Placebo	Merck	Phase 3	40
Lisinopril + Telmisartan + Placebo	Merck	Phase 3	40
Cetrorelix acetate + Cetrorelix acetate + Recombinant Human Choriogonadotropin (r-hCG) + Recombinant human follicle stimulating hormone (r-hFSH)	Merck	Phase 3	40
Gonal-f® + Long GnRH agonist + GnRH antagonist	Merck	Pre-clinical	26
Placebo + Everolimus	Novartis	Approved	43
LIK066 + Placebo	Novartis	Phase 2	35
Everolimus + Calcineurin inhibitors maintenance	Novartis	Phase 3	40
Everolimus + Octreotide LAR	Novartis	Phase 2	35
Atorvastatin + Placebo	Pfizer	Pre-clinical	26
Rapamune	Pfizer	Phase 1/2	32
Sirolimus	Pfizer	Phase 2/3	34